JP2019524883A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524883A5
JP2019524883A5 JP2019529309A JP2019529309A JP2019524883A5 JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5 JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019529309 A JP2019529309 A JP 2019529309A JP 2019524883 A5 JP2019524883 A5 JP 2019524883A5
Authority
JP
Japan
Prior art keywords
alkyl
cyclyl
heterocyclyl
group
membered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2019529309A
Other languages
English (en)
Japanese (ja)
Other versions
JP6959663B2 (ja
JP2019524883A (ja
Filing date
Publication date
Priority claimed from CN201610647295.0A external-priority patent/CN107698593A/zh
Application filed filed Critical
Publication of JP2019524883A publication Critical patent/JP2019524883A/ja
Publication of JP2019524883A5 publication Critical patent/JP2019524883A5/ja
Application granted granted Critical
Publication of JP6959663B2 publication Critical patent/JP6959663B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2019529309A 2016-08-09 2017-07-27 Ｆｇｆｒ阻害剤としての複素環化合物 Expired - Fee Related JP6959663B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201610647295.0A CN107698593A (zh) 2016-08-09 2016-08-09 作为fgfr抑制剂的杂环化合物
CN201610647295.0 2016-08-09
PCT/CN2017/094620 WO2018028438A1 (zh) 2016-08-09 2017-07-27 作为fgfr抑制剂的杂环化合物

Publications (3)

Publication Number Publication Date
JP2019524883A JP2019524883A (ja) 2019-09-05
JP2019524883A5 true JP2019524883A5 (cg-RX-API-DMAC7.html) 2020-07-16
JP6959663B2 JP6959663B2 (ja) 2021-11-02

Family

ID=61162708

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019529309A Expired - Fee Related JP6959663B2 (ja) 2016-08-09 2017-07-27 Ｆｇｆｒ阻害剤としての複素環化合物

Country Status (7)

Country Link
US (1) US10752631B2 (cg-RX-API-DMAC7.html)
EP (1) EP3498706A4 (cg-RX-API-DMAC7.html)
JP (1) JP6959663B2 (cg-RX-API-DMAC7.html)
KR (1) KR20190035870A (cg-RX-API-DMAC7.html)
CN (2) CN107698593A (cg-RX-API-DMAC7.html)
CA (1) CA3032921A1 (cg-RX-API-DMAC7.html)
WO (1) WO2018028438A1 (cg-RX-API-DMAC7.html)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102945203B1 (ko) 2017-05-08 2026-03-31 시애틀 프로젝트 코포레이션 알파바이러스 신생항원 벡터
KR20210090650A (ko) 2018-11-07 2021-07-20 그릿스톤 바이오, 인코포레이티드 알파바이러스 신생항원 벡터 및 인터페론 억제제
CA3129665A1 (en) 2019-03-21 2020-09-24 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
JP2022533939A (ja) * 2019-05-17 2022-07-27 キネート バイオファーマ インク． 線維芽細胞増殖因子受容体キナーゼの阻害剤
SG11202113187WA (en) 2019-05-30 2021-12-30 Gritstone Bio Inc Modified adenoviruses
KR20220098759A (ko) 2019-11-08 2022-07-12 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) 키나제 억제제에 대해 내성을 획득한 암의 치료 방법
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
EP4161657A1 (en) * 2020-06-05 2023-04-12 Kinnate Biopharma Inc. Inhibitors of fibroblast growth factor receptor kinases
CN116057045B (zh) 2020-06-05 2026-06-09 金耐特生物制药公司 成纤维细胞生长因子受体激酶抑制剂
IL300026A (en) 2020-08-06 2023-03-01 Gritstone Bio Inc Multiepitope vaccine cassettes
CN112480109B (zh) * 2020-11-16 2022-04-01 浙江大学 吡啶并[2,3-b]吡嗪-3(4H)-酮类衍生物及其用途
MX2023008186A (es) * 2021-01-12 2023-07-18 Beijing Innocare Pharma Tech Co Ltd Proceso para preparar (s)-1-(1-acriloilpirrolidin-3-il)-3-((3,5-di metoxifenil)etinil)-5-(metilamino)-1h-pirazol-4-carboxamida.
CN114853739B (zh) * 2021-02-03 2023-09-22 药雅科技(上海)有限公司 一种炔代吡嗪类fgfr抑制剂及其制备方法和用途
CN115043832B (zh) * 2021-03-08 2023-08-22 药雅科技(上海)有限公司 一种fgfr抑制剂炔代杂环类化合物及其制备方法和用途
CN120051471A (zh) * 2022-10-18 2025-05-27 首药控股(北京)股份有限公司 一种新型杂环化合物
CN121487738A (zh) 2023-03-30 2026-02-06 锐新医药公司 诱导ras gtp水解的组合物和其用途
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1981890A2 (en) * 2006-01-25 2008-10-22 OSI Pharmaceuticals, Inc. UNSATURATED mTOR INHIBITORS
AU2013210403B2 (en) 2012-01-19 2016-01-14 Taiho Pharmaceutical Co., Ltd. 3,5-disubstituted alkynylbenzene compound and salt thereof
JP6378308B2 (ja) * 2013-03-13 2018-08-22 ボストン バイオメディカル， インコーポレイテッド がんの処置のための、がん幹細胞経路キナーゼの阻害剤としての３−（アリールまたはヘテロアリール）メチレンインドリン−２−オン誘導体
DK3023100T3 (da) * 2013-07-18 2019-05-27 Taiho Pharmaceutical Co Ltd Antitumorlægemiddel til intermitterende administration af fgfr-hæmmer
JP6084292B2 (ja) 2013-07-18 2017-02-22 大鵬薬品工業株式会社 Ｆｇｆｒ阻害剤耐性癌の治療薬
CN104341425B (zh) * 2013-08-08 2018-11-02 上海医药集团股份有限公司 氘代乙炔衍生物、其药物组合物及应用
RU2677884C2 (ru) * 2013-09-30 2019-01-22 Гуанчжоу Иннокэа Фарма Тек Ко., Лтд. Замещенные никотинимидные ингибиторы втк, их получение и применение в терапии раковых, воспалительных и аутоиммунных заболеваний
EP3184521B1 (en) * 2014-08-19 2021-10-06 Shanghai Haihe Pharmaceutical Co., Ltd. Indazole compounds as fgfr kinase inhibitors, preparation and use thereof

Similar Documents

Publication Publication Date Title
JP2014193925A5 (cg-RX-API-DMAC7.html)
JP2016540742A5 (cg-RX-API-DMAC7.html)
JP2015508103A5 (cg-RX-API-DMAC7.html)
JP2016530259A5 (cg-RX-API-DMAC7.html)
JP2015520140A5 (cg-RX-API-DMAC7.html)
JP2016515561A5 (cg-RX-API-DMAC7.html)
JP2015505296A5 (cg-RX-API-DMAC7.html)
JP2019522055A5 (cg-RX-API-DMAC7.html)
JP2017071634A5 (cg-RX-API-DMAC7.html)
JP2014503574A5 (cg-RX-API-DMAC7.html)
JP2016505512A5 (cg-RX-API-DMAC7.html)
JP2014521688A5 (cg-RX-API-DMAC7.html)
MA38323B1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
CN109715626A (zh) 作为fgfr抑制剂的杂环化合物
JP2020097577A5 (cg-RX-API-DMAC7.html)
JP2016501221A5 (cg-RX-API-DMAC7.html)
JP2017531619A5 (cg-RX-API-DMAC7.html)
JP2019529444A5 (cg-RX-API-DMAC7.html)
JP2016503797A5 (cg-RX-API-DMAC7.html)
JP2016534063A5 (cg-RX-API-DMAC7.html)
JP2016510326A5 (cg-RX-API-DMAC7.html)
JP2014501766A5 (cg-RX-API-DMAC7.html)
JP2016531126A5 (cg-RX-API-DMAC7.html)
JP2019535723A5 (cg-RX-API-DMAC7.html)
JP2020532545A5 (cg-RX-API-DMAC7.html)